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Inhibition of DNA2 nuclease as a therapeutic strategy
targeting replication stress in cancer cells
S Kumar1,7, X Peng2,3,7, J Daley4, L Yang2,8, J Shen2, N Nguyen5, G Bae5, H Niu4,5,9, Y Peng2, H-J Hsieh2, L Wang2, C Rao6, CC Stephan5,
P Sung4, G Ira1 and G Peng2
Replication stress is a characteristic feature of cancer cells, which is resulted from sustained proliferative signaling induced
by activation of oncogenes or loss of tumor suppressors. In cancer cells, oncogene-induced replication stress manifests as
replication-associated lesions, predominantly double-strand DNA breaks (DSBs). An essential mechanism utilized by cells to repair
replication-associated DSBs is homologous recombination (HR). In order to overcome replication stress and survive, cancer cells
often require enhanced HR repair capacity. Therefore, the key link between HR repair and cellular tolerance to replication-
associated DSBs provides us with a mechanistic rationale for exploiting synthetic lethality between HR repair inhibition and
replication stress. DNA2 nuclease is an evolutionarily conserved essential enzyme in replication and HR repair. Here we demonstrate
that DNA2 is overexpressed in pancreatic cancers, one of the deadliest and more aggressive forms of human cancers, where
mutations in the KRAS are present in 90–95% of cases. In addition, depletion of DNA2 signiﬁcantly reduces pancreatic cancer cell
survival and xenograft tumor growth, suggesting the therapeutic potential of DNA2 inhibition. Finally, we develop a robust high-
throughput biochemistry assay to screen for inhibitors of the DNA2 nuclease activity. The top inhibitors were shown to be
efﬁcacious against both yeast Dna2 and human DNA2. Treatment of cancer cells with DNA2 inhibitors recapitulates phenotypes
observed upon DNA2 depletion, including decreased DNA double strand break end resection and attenuation of HR repair. Similar
to genetic ablation of DNA2, chemical inhibition of DNA2 selectively attenuates the growth of various cancer cells with oncogene-
induced replication stress. Taken together, our ﬁndings open a new avenue to develop a new class of anticancer drugs by targeting
druggable nuclease DNA2. We propose DNA2 inhibition as new strategy in cancer therapy by targeting replication stress, a
molecular property of cancer cells that is acquired as a result of oncogene activation instead of targeting currently undruggable
oncoprotein itself such as KRAS.
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INTRODUCTION
The ﬁnding that poly(ADP-ribose) polymerase inhibitors, a new
class of DNA repair inhibitors, speciﬁcally kill cancer cells with
BRCA1 or BRCA2 mutations but are less cytotoxic to normal cells
highlighted the promise of DNA repair inhibitors for targeted
cancer treatment.1,2 This ﬁnding also provides proof of the
principle that synthetic lethality interactions in the DNA repair
network can be exploited for targeted cancer therapy. Early in the
process of tumorigenesis, genetic alterations such as activation of
oncogenes and loss of tumor-suppressor genes are implicated in
inducing replication stress by providing premalignant cells with
excessive growth signals.3,4 In cancer cells, oncogene-induced
replication stress manifests as a high level of DNA double-strand
breaks (DSBs) because of stalling and collapse of DNA replication
forks.5,6 A marked increase of replication stress and spontaneous
DNA damage in cancer cells, which renders them more dependent
on DNA repair for survival.7 Among all DNA repair pathways,
homologous recombination (HR)-mediated DNA repair is an
essential mechanism utilized by cancer cells to repair
replication-associated DSBs and thereby to overcome replication
stress and survive. The key link between HR repair and cellular
tolerance to replication-associated DSBs provides us with a
mechanistic rationale for exploiting synthetic lethality between
HR repair inhibition and replication stress in cancer cells.
Moreover, owing to their hyper-proliferative state, cancer
cells are more vulnerable to killing by DNA-damaging
agents. Common cancer treatment strategies use untargeted
radiomimetic chemotherapy or radiotherapy that induce a broad
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range of DNA lesions including DSBs. The ability of cancer cells to
repair DNA damage lowers therapeutic efﬁcacy, thus the
simultaneous use of a DNA repair inhibitor holds great promise
in sensitizing cancer cells to conventional chemo/radiotherapy.
Inhibitors that target enzymes mediating base excision repair,
nucleotide excision repair and other DNA repair pathways have
been developed and are being evaluated in clinical trials.8–10
Therefore, identiﬁcation of new HR repair inhibitors can open new
avenues to cancer therapies.4,11–15
An evolutionarily conserved protein DNA2 possesses 5′ ﬂap
endonuclease and 3′–5′ helicase activities and it has an important
role in DNA damage repair, HR and DNA replication. The nuclease
activity of DNA2 has several well-documented cellular functions,
whereas the biological role of its helicase activity remains
enigmatic. Speciﬁcally, DNA2 mediates the resection of the 5′
strand at DNA DSB ends,16–23 an early step in HR, and also at
stalled and regressed replication forks.24,25 Dna2 in fungi
processes long 5′ DNA ﬂaps during the maturation of Okazaki
fragments in lagging strand DNA synthesis,26,27 whereas human
DNA2 (hDNA2) has an essential but as yet undeﬁned role in DNA
replication.28 hDNA2 has an additional function in mitochondrial
DNA maintenance.29 Finally, the unstructured and regulatory
N-terminal domain of yeast Dna2 (yDna2) was recently shown to
regulate DNA damage response by activating the Mec1 kinase
(Mec1 is orthologus to human DNA damage checkpoint kinase
ATR).30 Among these important biological functions of DNA2,
the nucleolytic processing of the 5′ strands at spontaneous DSBs
or regressed replication forks seems to be the most relevant in
alleviating replication stress. Consistent with this notion, Dna2 is
overexpressed via gene duplication in yeast upon replication
stress caused by the mec1-21 mutation.31 Interestingly, similar to
this observation in yeast cells, studies from our group and others
have demonstrated that DNA2 is overexpressed in a broad
spectrum of malignancies including breast cancer, ovarian cancer,
lung cancer, prostate cancer, glioblastoma, pancreatic cancer,
leukemia, colon cancer, melanoma, Lynch syndrome and heredi-
tary nonpolyposis colorectal cancer.32–34 DNA2 overexpression is
needed for the tolerance of increased replication stress induced
by oncogene activation such as H-Ras or cyclin E in osteosarcoma
and breast cancer cells, and partial depletion of DNA2 reduces the
tumorigenicity of breast cancer cells.33 These results have raised
the prospect of targeting DNA2 in cancer therapy.
As the increased nuclease activity of DNA2 is required in yeast
and cancer cells to overcome replication stress and DNA damage,
for the ﬁrst time, we developed a robust biochemistry-based
screening method for chemical inhibitors of DNA2. We conducted
initial screen with nearly 50 000 compounds and we tested
efﬁcacy of several candidate inhibitors in pancreatic and
breast cancer cell lines with oncogene-induced replication
stress. Treatment of cancer cells with the top DNA2 inhibitor
recapitulates many phenotypes observed upon DNA2 depletion,
and attenuates the growth of various cancer cells. Taken together,
in this study, we developed a feasible high-throughput chemical
screen assay to identify novel DNA repair inhibitors and more
importantly we provided a new synthetic lethal strategy based on
inhibition of HR repair by DNA2 inhibitors in cancer cells with
oncogene-induced replication stress.
RESULTS
Sensitivity of pancreatic cancer cells to DNA2 depletion
Pancreatic cancer is particularly deadly because of the lack of an
effective treatment regimen. Here, we investigated the expression
levels and therapeutic potential of DNA2 depletion in pancreatic
cancers, where 90–95% cases are associated with an activating
mutation in the K-Ras oncogene.35–37 Analysis of gene expression
patterns in pancreatic cancers in the Oncomine database
shows that DNA2 is signiﬁcantly upregulated.33 Consistently, an
elevated DNA2 protein level was observed in pancreatic cancer
patient specimens (Figure 1a). Moreover, patients with chronic
pancreatitis expressed DNA2 at an elevated level in their
pancreatic tissue (Figure 1a). To establish the relationship between
the K-Ras oncogene and DNA2 expression, we analyzed a
transgenic K-RasG12D pancreatic cancer mouse model. Similar to
pancreatic cancer patient specimens, the DNA2 protein level was
greatly increased in K-RasG12D-activated early pancreatic cancer
lesions, suggesting that DNA2 overexpression is an early event
during tumorigenesis (Figure 1b). Importantly, the depletion of
DNA2 impaired the growth and survival of cells from two
pancreatic cancer lines, and also led to increased senescence
and apoptosis of these cells (Figure 1c, Supplementary Figure S1a).
Consistent with in vitro cell culture ﬁndings, DNA2 knockdown
signiﬁcantly reduced tumor growth in the xenograft model
(Supplementary Figure S1b). Furthermore, our analyses showed
increased staining of p-CHK1, a key molecule in DNA damage
signaling, and reduced staining of Ki67, a marker of cell
proliferation, in DNA2-depleted cells is likely due to endogenous
DNA damage (Supplementary Figure S1c). Thus, DNA2 over-
expression is a common theme in many cancer types including
pancreatic cancer and inhibition of DNA2 reduces pancreatic
cancer cell survival both in vitro and in vivo.
Isolation of yDna2 inhibitors
We have presented evidence that DNA2 overexpression alleviates
the impaired proliferation of U2OS and MCF10A cells after an
activation of either H-Ras or cyclin E,33 suggesting that DNA2
could be an effective target in cancer therapy. This prompted us to
develop a simple screen for chemical inhibitors of DNA2. The
screen entailed the use of oligonucleotide (dT)30 having a reporter
ﬂuorescent moiety, 6-FAM on the 5′ end, and the dark quenching
group, Iowa Black FQ, on the 3′ end. In addition, a second dark
quencher ZEN was placed between the 9th and 10th base
(Figure 2a). The ﬂuorescence emitted by 6-FAM is quenched by
FRET, but it increases when DNA is degraded by Dna2. In the initial
screen, compounds were tested at a ﬁxed concentration of
inhibitors (33.33 μM) with a subsaturating amount (0.09 nM) of
Dna2. The inhibitory activity of the compounds was determined
as a reduction in ﬂuorescent signal compared with the
dimethylsulfoxide (DMSO) only control. The primary screen hits
were selected based on a ⩾ 50% inhibition of the Dna2 activity.
We screened ~ 50 000 chemical compounds from six different
libraries (Supplementary Table S1) to identify chemical inhibitors
of the Dna2 nuclease activity. As we could not purify hDNA2 in
amounts sufﬁcient for a high-throughput screen, the initial screen
was performed with yDna2, followed by testing top candidate
compounds with hDNA2. The DNA2 nuclease domain is well
conserved among eukaryotes, and therefore we reasoned that
inhibitors of yDna2 will likely also work with the human
counterpart. DNA2 nuclease efﬁciently cleaves the single-stranded
DNA substrate used here (Figure 2b and Stewart et al.38), and
inhibitors are expected to block substrate cleavage. First, we
determined the concentration of yDna2 and hDNA2 and of the
control T5 nuclease needed to generate maximum ﬂuorescence
(Figure 2c), and we optimized the screen reaction (Z′ value of 0.8)
in a robotic system with a 384-well plate setup to provide high
throughput. The ﬁrst screening round identiﬁed 184 compounds,
corresponding to a hit rate of ~ 0.4%. These compounds were
subject to re-screening to conﬁrm their efﬁcacy and also to
eliminate those compounds that also inhibit T5 nuclease. We were
able to narrow yDna2-speciﬁc candidate compounds down to 39
(Supplementary Table S2).
We note that a number of the compounds listed in
Supplementary Table S3 inhibited the activity of both yDna2
and T5 and are therefore nonspeciﬁc. Interestingly, many of these
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nonspeciﬁc inhibitors interact with DNA and are already used in
cancer therapy, including multiple drugs known to inhibit type II
topoisomerases (for example, daunorubicin, doxorubicin and
mitoxantrone). Here, we have provided evidence that these
compounds also affect the activity of Dna2. Thus, in addition to
inducing DSBs by blocking topoisomerase II, it is likely that
these drugs affect the processing and repair of these DSBs by
nucleases.
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Cellular screen for the most potent DNA2 inhibitors
The biological effectiveness of the 39 compounds selected by
re-screening was determined by measuring their half maximal
inhibitory concentration (IC50) biochemically and in a cell-based
system using the 384-well platform (Supplementary Table S2). We
used the cancer cell line, U2OS, as cells of this lineage overexpress
DNA2 signiﬁcantly and are sensitive to partial DNA2 depletion.33
We conducted the viability assay in duplicate on three separate
occasions using a concentration range of 10 pM to 10 μM for each
compound. Cell proliferation was determined using 4,6-diamidino-
2-phenylindole staining and microscopy. About 10 compounds
showed IC50 values between o1 and 10 μM both in cells and
in vitro (Supplementary Table S2), and two of them, NSC-5195242
and NSC-105808 (Figures 3a and b), were selected for further
analysis.
Inhibitory effect of NSC-5195242 and NSC-105808 on hDNA2
The initial inhibitor screen was done with yDna2, thus it was
important to test whether NSC-5195242 and NSC-105808 would
affect the activity of hDNA2. hDNA2, puriﬁed as described,39 was
ﬁrst tested using the triply labeled substrate as above (Figure 2a).
We found a similar inhibitory effect on hDNA2 and comparable
IC50 values as determined for yDna2 (Figure 3c). Furthermore, we
tested the impact of these two compounds in a reconstituted 5′
DNA end resection assay including hDNA2, Bloom syndrome and
Replication protein A (RPA) as described39 and in 5′ ﬂap
processing by hDNA2. Both compounds inhibited resection in
the reconstituted system (Figure 3d) and also 5′ ﬂap processing
(Supplementary Figure S2). Considering that compound
NSC-105808 shows a lower IC50 in vitro and biologically, further
tests were focused on this compound. We found that NSC-105808
has no effect on ATPase activity of DNA2, nor the ability of Bloom
syndrome to unwind DNA, nor does it affect DNA binding by
DNA2 (Supplementary Figure S2). Furthermore, NSC-105808 does
not inhibit the nuclease activity of EXO1 (Supplementary
Figure S2), which can also catalyze DNA ends resection. Together,
these data provide further evidence that NSC-105808 speciﬁcally
inhibits the nuclease activity of DNA2.
NSC-105808 interferes with DNA end resection and HR in cells,
and suppresses the cisplatin sensitivity of FANCD2− /− cells
To test whether NSC-105808 inhibits proliferation of U2OS cells
by targeting DNA2, we ﬁrst examined whether the ectopic
overexpression of DNA2 could reduce the negative effect of
Figure 2. Assay optimization for high-throughput screen for DNA2 inhibitors. (a) Graphical representation of the screen assay. The 30
nucleotides long ssDNA substrate is labeled with three dyes: a ﬂuorophore (6-FAM) at the 5′end, and two dark quenchers, internal ZEN
(between 9th and 10th base) and Iowa Black FQ at the 3′ end. The extent of the reaction was determined by measuring increase of
ﬂuorescence at wavelength of 520 nm. (b) hDNA2 (0, 0.5 or 1 nM) was incubated with radiolabeled ssDNA (2.5 nM). The radiolabel is denoted
by *. (c) Degradation of triply labeled ssDNA (100 nM) by yDna2 (0.002 to 5.0 nM), hDNA2 (0.00016 to 166 nM) and T5 nuclease (0.01–10 units).
Figure 1. DNA2 is overexpressed in pancreatic cancer lesions. (a) Immunohistochemistry (IHC) staining of DNA2 in representative human
pancreatic lesion specimens. Two cases are presented and the lesions (boxed) are also shown at a higher magniﬁcation. (i, ii) normal
pancreatic tissue; (iii, iv) hyperplasia in pancreatic tissue with chronic pancreatitis; (v, vi) pancreatic carcinoma. (b) IHC staining of DNA2 in
wild-type mouse pancreatic tissue (top) and in LSL-K-RasG12D mouse pancreatic cancer tissue (bottom). Scale bar, 100 μm. Segments (boxed) of
the images are also shown at a high magniﬁcation. (c) DNA2 depletion affects the survival of pancreatic cancer cells. Pancreatic cancer cell
lines AsPC-1 and PANC-1 were stably transfected with short hairpin RNA (shRNA) vectors against two non-overlapping sequences in DNA2 or
scramble control (Mock) (see also Supplementary Figure S1). (Left) Clonogenic assay, cell survival scored 10–15 days after seeding. (Middle)
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, cells proliferation measured 72 h after seeding. (Right) Senescence
assay with β-galactosidase staining and apoptosis assay using annexin V staining performed 72 h after DNA2 knockdown. Each value
represents the mean± s.e.m. from three independent experiments (*Po0.05; **Po0.01; ***Po0.005; ****Po0.001).
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NSC-105808 on cell growth. An approximately 1.5–2.0-fold
increase in DNA2 protein level was able to attenuate the negative
impact of NSC-105808 on cell proliferation, supporting the idea
that DNA2 is the target of NSC-105808 in cells (Supplementary
Figure S3). DNA2 functions in DSB end resection and HR,17,18,33
thus we asked whether NSC-105808 interferes with these
biological processes. Similar to DNA2 knockdown, NSC-105808
(24-h treatment) signiﬁcantly reduced DSB repair by gene
conversion or single stand annealing as determined by using
two green ﬂuorescent protein-based reporter assays (Figure 4a,
Supplementary Figures S4-6 and Peng et al.33). The treatment with
NSC-105808 had only a mild impact on cell cycle distribution at
Figure 3. Validation of the top two inhibitors identiﬁed from the high-throughput screen. (a) Chemical structure of NSC-5195242
(2-nitrophenanthrene-9,10-dione) and NSC-105808 (6-amino-7-bromoquinoline-5,8-dione). (b, c) Dose-response curves for indicated
compounds, cell based (U2OS cell line) (b) and in vitro (c). The IC50 value and the protein concentration used are indicated. Triple labeled
substrate (0.1 μM) as in Figure 2a was used. The concentration range of inhibitors was 0.003–666.67 μM. (d) Degradation of radiolabeled 2-kb
dsDNA (0.5 nM ends) with hDNA2 (5 nM), Bloom syndrome (5 nM) and RPA (100 nM) and the indicated concentrations of NSC-5195242 and
NSC-105808. The asterisks denote the radiolabel. Plotted are the average data from three independent experiments and the error bars
represent 1 s.d.
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the highest tested concentration (0.6 μM) with a slight decrease of
G1 and increase of G2 cells, but with no impact on the cellular
level of DNA2 protein (Supplementary Figures S7 and 8). We note
that longer (448 h) exposure to NSC-105808 causes cell death
(Figure 3b). To test DSB end resection, we followed phosphoryla-
tion of the single-stranded DNA (ssDNA)-binding protein RPA (p-
RPA) as described previously.40 Cells were treated with the
topoisomerase I inhibitor camptothecin, which induces DNA nicks,
reversed replication forks and single-ended DSBs. As shown in
Figure 4b, NSC-105808 treatment signiﬁcantly attenuated the
accumulation of camptothecin-induced p-RPA, suggesting an
impairment of DSB end resection. We then conﬁrmed this result
by conducting chromatin fractionation and observed that
NSC-105808 reduced p-RPA accumulation in the chromatin
fraction with a concomitant enhancement in the γ-H2AX level,
reﬂective of an accumulation of unrepaired DSBs (Figure 4c).
Altogether, the above results provide evidence that NSC-105808
interferes with DSB resection and HR in cells.
We wished to further verify the DNA2 speciﬁcity of NSC-105808
in cells. Previous work revealed that DNA2 depletion in FANCD2-
deﬁcient cells partially suppresses the sensitivity of these cells to
cisplatin.41 As shown in Figure 4d, FANCD2− /− cells were more
sensitive to cisplatin treatment compared with control cells,
and, importantly, a very low concentration of NSC-105808
lessened the cisplatin sensitivity of these cells. Together, our
results are consistent with the premise that DNA2 is the target of
NSC-105808 in cells.
Oncogene induction renders cells susceptible to NSC-105808
DNA2 overexpression, often observed in cancer cells, has
been proposed to alleviate oncogene-induced replication stress.
Increased sensitivity of cancer cells to DNA2 depletion33 can likely
be explained by an increased amount of substrates that are
processed by DNA2 nuclease/helicase. We therefore asked
whether NSC-105808 can sensitize cancer cells to oncogene-
Figure 4. NSC-105808 inhibits HR repair and DSB end resection. (a) Analysis of HR efﬁciency with the DR-green ﬂuorescent protein (GFP) assay.
Representative images of ﬂow cytometry analysis and bar graph showing percentage of GFP cells from at least three independent
experiments. Each value represents the mean± s.d. (b, c) Analysis of RPA phosphorylation in U2OS cells treated with NSC-105808 (2 h, 0.3 μM)
and/or camptothecin (CPT; 2 h, 1 μM). (b) Representative images of cells subjected to immunoﬂuorescent staining of p-RPA and bar graph
showing percentage of cells with positive p-RPA staining from three independent experiments. Each value represents the mean± s.d.
(c) Western blot analysis of chromatin fraction with the indicated antibodies. (d) Analysis of colony formation by FANCD2 (+/+) and
FANCD2 (− /− ) cells treated with cisplatin and/or NSC-105808. Each value is relative to the untreated control group of each cell line. The
graph represents the mean± s.e.m. from three independent experiments. *Po0.01.
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induced replication stress. Initially, we compared the impact of our
DNA2 inhibitor in pancreatic or breast cancer cells versus control
cells (Figures 5a and b). Transformed pancreatic cancer cell lines
(AsPC-1, PANC-1) were more sensitive to NSC-105808 when
compared with non-transformed pancreatic ductal epithelial cells
(DT-PD59). Similarly, transformed breast cancer cells (Hs578T and
BT549) were more sensitive than MCF10A non-transformed breast
epithelial cells to the DNA2 inhibitor.
Three separate cell models were then used to test whether
NSC-105808 can target cancer cells with oncogene activation
(Figures 5c-e). First, we generated an MCF10A cell line, an immor-
talized non-transformed breast epithelial cell line, with inducible
H-Ras expression. Induction of H-Ras expression is shown in
Supplementary Figure S9a. Upon activation of H-Ras, cells
exhibited increased sensitivity to the DNA2 inhibitor (Figure 5c).
Second, we used the E6/E7 oncoprotein to induce replication
stress in non-transformed pancreatic ductal cells (DT-PD59) as
previously described.42 Again, sensitivity to NSC-105808 was
higher in cells with oncoprotein-induced replication stress
(Figure 5d). In addition, we also established an inducible K-Ras
expression cell line using non-transformed pancreatic ductal
epithelial cells (Supplementary Figure S9a). Both 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony
formation assays showed that activation of K-Ras expression
sensitized pancreatic ductal epithelial cells to NSC-105808
treatment (Supplementary Figures S9b and 9c). Finally, we tested
a series of epithelial cell lines that represent different stages of
breast cancer progression:43 control non-tumorigenic MCF10A
cells; premalignant/tumorigenic MCF10AT1 cells, derived from
MCF10A cells by the expression of oncogenic H-Ras; tumorigenic/
locally invasive MCF10-DCIS cells, and tumorigenic/metastatic
MCF10CA1a cells, cloned from xenograft lesions induced by
premalignant MCF10AT1 cells. Consistent with other observations,
the three cell lines with oncogene activation were more sensitive
to DNA2 inhibitor treatment compared with the MCF10A control
(Figure 5e). Thus, in different cell models, oncogene activation
sensitizes cells to NSC-105808.
DISCUSSION
During tumorigenesis, the activation of an oncogene or loss of a
tumor-suppressor gene leads to excessive growth signals and
replication stress. Notably, about 30% of all cancers have an
activating mutation in Ras and the vast majority (up to 95%) of
pancreatic cancer patients harbor a mutation in K-Ras.35–37
Unfortunately, thus far, no effective inhibitor of the K-Ras
oncoprotein has reached the clinic. In this study, we have strived
to test the efﬁcacy of DNA2 nuclease inhibition in cancer cells that
experience oncogene-induced replication stress. As such stress is a
common denominator among multiple cancer types, DNA2
inhibition could be an efﬁcacious strategy to treat a broad
spectrum of cancers. Besides targeting cancer cells with an
activated oncogene, chemical inhibition of DNA2 may also be
useful for sensitizing cells to DNA damage when combined with
radiomimetic chemotherapy or radiation therapy. As we expected,
recent studies reported that DNA2 inhibition can sensitize breast
cancer cells to chemotherapy inducing DNA damage.44 We
developed a simple high-throughput screening assay for DNA2
inhibitors, which can screen compound collections in very small
reaction volume and in general to screen for inhibitors of other
nucleases. We identiﬁed several compounds with the ability to
inhibit DNA2 in DNA incision and also in a reconstituted system of
DNA end resection. The NSC-105808 compound inhibits DNA2
but not other tested nucleases, however, additional cellular
targets cannot be excluded. Importantly, NSC-105808 treatment
recapitulates several phenotypes of cells with DNA2 depletion,
such as attenuated DSB end resection, decreased HR and
suppression of the sensitivity of FANCD2-deﬁcient cells to
cisplatin.41 DNA2 has an important role in telomere replication,45
thus the effect of NSC-105808 on telomere stability cannot be
excluded. The inhibitor reduces the growth of various cancer cells,
and speciﬁcally those cells in which replication stress is induced
via oncogene activation. A similar range of IC50 values for the
NSC-105808 in vivo and in in vitro assay may indicate that even
minimal inhibition of DNA2 in cells could be lethal to cells. For
Figure 5. Oncogene induction enhances sensitivity of cancer cells to NSC-105808. (a-e) Graphs showing proliferation of indicated cell lines in
response to a 48-h treatment with the indicated concentrations of NSC-105808. Proliferation relative to cells treated with vehicle alone was
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Each value represents the mean± s.e.m. from
three independent experiments. (a) Proliferation of control pancreatic epithelial cells DT-PD59 and transformed pancreatic cancer cells AsPC-1
and PANC-1. (b) Proliferation of normal breast epithelial cells MCF10A and breast cancer cells Hs578T and BT549. (c) Proliferation of MCF10A
cells with or without H-Ras expression. H-Ras was induced with doxycycline (2 μg/ml). (d) Proliferation of control pancreatic DT-PD59 cells
and transformed DT-PD77 cells with E6/E7 oncoprotein activation. (e) Proliferation of MCF10A breast cells without and with H-Ras activation
(AT1, DCIS, CA1a).
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example, a single unrepaired DSB is lethal for cells. Alternatively
DNA2 sensitivity to the drug can be altered by cell-speciﬁc
features, such as DNA2 posttranslational modiﬁcations. Together
our work suggests that temporary inhibition of DNA2 nuclease
represents a promising strategy in cancer therapy.
MATERIALS AND METHODS
Human cell cultures
U2OS and MCF10A cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and were maintained in McCoy’s 5A
medium supplemented with 10% fetal bovine serum. MCF10A cells were
cultured in mammary epithelial growth medium containing insulin,
hydrocortisone, epidermal growth factor and bovine pituitary extract
purchased from Clonetics (Lonza Group Ltd, Basel, Switzerland). MCF10A
cells with stable H-Ras expression were generated by infection with
lentiviral inducible-V5 construct (Life Technologies, Grand Island, NY, USA)
and maintained in the presence of G418 (200 μg/ml) and blasticidin (4 μg/
ml). AsPC-1 and PANC-1 cells were cultured in Dulbecco's modiﬁed Eagle's
medium (Corning Cellgro, Manassas, VA, USA) with 10% fetal bovine
serum, vitamin (100× ), non-essential amino acids (100 × ) and Penicillin/
Streptomycin (100 × ). BT549 cells were cultured in RPMI-1640 medium
with 0.023 IU/ml insulin and Hs578T cells in Dulbecco's modiﬁed Eagle's
medium medium with 0.01 mg/ml bovine insulin. The pancreatic cell lines
(DT-PD59, DT-PD77-E6/E7) were kindly provided by Dr Michel J Quellette
(University of Nebraska Medical Center, Omaha, NE, USA) and cultured as
described.46 Pancreatic ductal epithelial cells with inducible K-Ras
expression were generated and maintained in the Keratinocyte-SFM
medium (Life Technologies) as previously described.47 A series of breast
epithelial cell lines transformed by H-Ras (MCF10A, MCF10AT1, MCF10-
DCIS and MCF10CA1a) were obtained from Dr Isabelle Bedrosian
(Department of Surgical Oncology, MD Anderson Cancer Center, Houston,
TX, USA) and maintained as described.43 In the experiments described in
Figures 5b and c, MCF10A cells were obtained from ATCC. FANCD2− /−
and control cell lines were obtained from Dr Randy Legerski (Department
of Genetics, MD Anderson Cancer Center). Cells were maintained in
Dulbecco's modiﬁed Eagle's medium containing 10% heat-inactivated fetal
bovine serum and 1% penicillin/streptomycin at 37 °C in 5% CO2. All cell
lines were validated by short tandem repeats DNA ﬁngerprinting using the
AmpF short tandem repeats Identiﬁler kit according to the manufacturer
instructions (Applied Biosystems, Foster City, CA, USA; cat. # 4322288). The
short tandem repeats proﬁles were compared with known ATCC
ﬁngerprints, to the Cell Line Integrated Molecular Authentication database
(CLIMA) and to the MD Anderson ﬁngerprint database. The short tandem
repeats proﬁles matched known DNA ﬁngerprints or were unique.
Plasmids, short hairpin RNA and transfection
The pLenti6.3/TO/V5-H-Ras vector was obtained from Dr Shiaw-Yih Lin
(Department of Systems Biology, MD Anderson Cancer Center). Brieﬂy,
PCMV-H-RAS (V12) was purchased from Invitrogen (Waltham, MA, USA)
and subcloned into the pLenti6.3/TO/V5-DEST vector (Invitrogen) based on
the commercial protocol of ViraPower TM HiPerform TM T-Rex TM Gateway
Expression system (Thermo Fisher Scientiﬁc Waltham, MA, USA). pLenti3.3/
TR and pLenti6.3/TO/V5-H-Ras were stably integrated into MCF10A cells.
Expression of H-Ras was induced by the addition of doxycycline (1 μg/ml)
for 48 h. The vector that expresses FLAG-tagged DNA2 has been
described.33 DNA2 short hairpin RNA vectors and control short hairpin
RNA vectors against luciferase sequences were obtained from Sigma (St
Louis, MO, USA; shDNA2#1: 5′-CCGGACCTGGTGTTGGCAGTCAATACTCGAGT
ATTGACTGCCAACACCAGGTTTTTTTG-3′; shDNA2#2: 5′-CCGGAGTTTGTGATG
GGCAATATTTCTCGAGAAATATTGCCCATCACAAACTTTTTTTG-3′). On-target
smart pool small interfering RNAs against DNA2 were purchased from
Dharmacon Research (Lafayette, CO, USA; #9: 5′-AGACAAGGUUCCA
GCGCCA-3′; #10: 5′-UAACAUUGAAGUCGUGAAA-3′; #11: 5′-AAGCACAGG
UGUACCGAAA-3′; #12: 5′-GAGUCACAAUCGAAGGAUA-3′). Transfection of
plasmids was performed with the FuGENE 6 reagent from Roche
(Indianapolis, IN, USA). Transfection of small interfering RNAs was
performed with Oligofectamine (Invitrogen).
Immunohistochemical staining
Tissue microarrays of formalin-ﬁxed, parafﬁn-embedded pancreatitis,
pancreatic tumors with their corresponding nonneoplastic tissues were
obtained from US Biomax (Rockville, MD, USA). Formalin-ﬁxed, parafﬁn-
embedded slides of a conditional LSL-K-RasG12D/transgenic pancreatic
cancer mouse model was obtained from Dr Chinthalapally Rao (Depart-
ment of Internal Medicine, University of Oklahoma, Oklahoma City, OK,
USA). After slides were deparafﬁnized with xylene and rehydrated with
ethanol, antigen retrieval was carried out by placing the slides in 0.1 M
sodium citrate (pH 6.0) in a water bath for 30 min at 95 °C. Endogenous
peroxidase activity was quenched with 3% hydrogen peroxide in
phosphate-buffered saline for 10 min. Slides were washed three times
with phosphate-buffered saline and incubated in blocking buffer contain-
ing 10% goat serum for 30 min. The slides were incubated with DNA2
antibody (1:200) overnight at 4 °C in a wet box, and immunohistochemical
staining was done by using the Vectastain ABC avidin biotin-peroxidase
enzyme complex kit (Vector Laboratories, Burlingame, CA, USA). Slides
were counterstained with hematoxylin and mounted with Permount
aqueous medium.
Cell proliferation assay
Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (Sigma) reduction (Supplementary
Materials and Methods).
Colony-forming assay
Transfection and colony-forming assay were performed as previously
described33 (Supplementary Materials and Methods).
Senescence assay
The assay was performed with a senescence β-galactosidase staining kit
(#9860; Cell Signaling, Danvers, MA, USA) according to the manufacturer’s
protocol (Supplementary Materials and Methods).
Flow cytometric analysis of apoptosis and BrdU incorporation
Apoptosis was measured by ﬂow cytometry using the Annexin V FITC assay
kit based on the protocol from the manufacturer (Invitrogen). For BrdU
(bromodeoxyuridine (5-bromo-2′-deoxyuridine)) analysis, after treatments,
cells were labeled with BrdU (Sigma) for 30 min before ﬁxation with 70%
cold ethanol (−20 °C). The next day, cells were washed with cold
phosphate-buffered saline and incubated with 2 M HCl for 5 min at room
temperature. After adjusting the pH with 0.1 M sodium borate (pH 8.5), cells
were incubated in 1% bovine serum albumin with 0.1% Triton X-100 for
30 min and mouse anti-BrdU antibody (1:400) for 1 h to detect BrdU
labeling. After washing, cells were incubated with secondary antibody
(ﬂuorescein isothiocyanate 1:400) for 30 min. Cells were resuspended in
staining solution (10 μg/ml propidium iodide, 20 μg/ml RNase A and 0.05%
Triton X-100) and cell cycle analysis was performed at the MD Anderson
Cancer Center Flow Cytometry and Cellular Imaging Facility. For
ﬂuorescence-activated cell sorting analysis, the percentage of cells with
positive BrdU staining in each phase of the cell cycle was quantitated with
the CellQuest software and ModFit software (Verity Software House Inc.,
Topsham, ME, USA).
Gene conversion and single stand annealing repair assays
The DR-green ﬂuorescent protein, pCAGGS and pCBASce plasmids were
kindly provided by Dr Maria Jasin (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA). U2OS cells containing a single copy of the HR
repair reporter substrate DR-green ﬂuorescent protein were generated as
previously described.48 Single stand annealing reporter cells were kindly
provided by Dr Jeremy Stark (Beckman Research Institute of the City of
Hope, Duarte, CA, USA).49 Details in Supplementary Materials and Methods.
Immunoﬂuorescent staining and chromatin fractionation
For the detection of DNA damage-induced p-RPA34 (S4/S8), immuno-
ﬂuorescent staining, and the preparation of chromatin fractions and
western blot analyses were performed as described previously.33,48
High-throughput screen for inhibitors of DNA2
The screen entailed the use of oligonucleotide (dT)30 having a
reporter ﬂuorescent moiety, 6-FAM (excitation max. = 494 nm, emission
max. = 520 nm) on the 5′ end, and the dark quenching group, Iowa Black
FQ (absorption max. = 531 nm), on the 3′ end. In addition, a second dark
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quencher ZEN (N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine,
absorption max. = 532 nm) is placed between 9th and 10th base
(Figure 2a). Initial screen, it was performed with yDna2.22 Then, the
top candidate compounds were tested on hDNA2. Identical reaction
conditions were used for assaying the nuclease activity of yDna2 and
hDNA2. We note that yDna2 is more active on the ssDNA substrate than
hDNA2, thus the experiment with ssDNA substrates were done with 10 nM
of hDNA2. The reaction buffer was 20 mM HEPES/NaOH, pH 7.5, 60 mM KCl,
1 mM DTT, 100 μg/ml bovine serum albumin and 0.05% Triton X-100. The
nuclease assay was initiated by adding MgCl2 (3 mM ﬁnal concentration).
T5 nuclease was assayed in the buffer (50 mM potassium acetate, pH 7.9,
20 mM Tris-acetate, 10 mM magnesium acetate and 1 mM DTT) provided by
the vendor (NEB, Ipswich, MA, USA). The concentration of the ﬂuorogenic
substrate was 0.1 μM. The optimal amount of yDna2, hDNA2 and T5
nuclease was determined by utilizing the Kaleidagraph software (Reading,
PA, USA) to ﬁt the data according to Michaelis Menton Kinetics
(V = V0+Vmax*x/(Km+x)). For curve ﬁtting, the maximum increase in
ﬂuorescence (upon adding 5 nM of yDna2 or 166 nM of hDNA2 or 10 units
of T5 nuclease) corresponds to Vmax, the background ﬂuorescence (without
enzyme) corresponds to V0 and ‘x’ is the enzyme concentration (nM). All
the compounds were dissolved in DMSO and DMSO alone was used as
control; the ﬁnal concentration of DMSO was at 3.33% for protein-based
assay and 0.1% for cell-based assay. The Z’ value was calculated as
previously described.50 Cell proliferation was determined using 4,6-
diamidino-2-phenylindole staining followed by high-throughput micro-
scopy in a 384-well plate setup. In brief, cells were ﬁxed with
formaldehyde, washed and stained with 4,6-diamidino-2-phenylindole
and the number of nuclei in each well counted by automated microscopy.
The data were analyzed as described.51
Nuclease substrates
The oligonucleotide PSOL6929 (5′-TTCATGGCTTAGAGCTTAATTGCTGAA
TCT-3′) was 5′ end-labeled with γ32P-ATP (Perkin-Elmer, Waltham, MA,
USA) and T4 polynucleotide kinase (NEB). The 2-kb dsDNA substrate is a
fragment of the hDNA2 gene created by PCR with oligonucleotides
PSOL4642 (5′-GATCCTCTAGTACTTCTC-3′) and PSOL6134 (5′-TCTACCT
CAAGACTGGTCAG-3′) using the DNA2 expression vector pJD7239 as
template; 50 μCi of α32P-dCTP (Perkin-Elmer) was included in the reaction
to randomly radiolabel the PCR fragment.
Nuclease assays
Nuclease assays were performed in buffer R (20 mM Na-HEPES pH 7.5, 1 mM
ATP, 0.1 mM DTT, 100 μg/ml bovine serum albumin, 0.05% Triton X-100,
2 mM MgCl2, 100 mM KCl) and contained 0.5 nM ends (2-kb substrate) or
5 nM ends (the ssDNA oligonucleotide PSOL6929) of DNA. Reactions
containing Bloom syndrome also included an ATP regenerating system
consisting of 10 mM creatine phosphate and 50 μg/ml creatine kinase. In
control reactions, DMSO was used in place of the inhibitor. Reactions with
DNA2 alone were incubated at 30 °C, and those with DNA2-Bloom
syndrome-Replication protein A and EXO1 were incubated at 37 °C for the
indicated times. After the addition of sodium dodecyl sulfate to 0.02%,
proteinase K to 0.25 μg/μl, and 0.08% Orange G dye with a ﬁnal glycerol
concentration of 10%, the reaction mixtures were incubated for 5 min at
37 °C. Electrophoresis was done in native 10% polyacrylamide gels in
Tris-borate-EDTA buffer (ssDNA substrate) or in 1% agarose gels in
Tris-acetate-EDTA buffer (40 mM Tris-acetate, pH 7.4, 0.5 mM EDTA) (2 kb
substrate). Gels were dried onto DEAE paper on top of Whatman ﬁlter
paper (GE, Issaquah, WA, USA) and then analyzed in a BioRad Personal
Molecular Imager FX phosphorimager. Band intensity was quantiﬁed using
Image Lab software (Bio-Rad, Hercules, CA, USA). The fraction of DNA
substrate digested was determined by measuring the amount of substrate
remaining and normalizing to the total substrate in the negative control
lane containing no protein.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
The research presented here was supported by CPRIT grant RP140456 to GI and GP,
R01 GM080600 to GI, the University of Texas MD Anderson Cancer Center Duncan
Family Institute for Cancer Prevention and Risk Assessment grant to GP, CPRIT grant
RP110532 to CCS, NIH grants ES015632 and ES015252 to PS. The authors thank
Dr Kenneth L Scott (Baylor College of Medicine) for providing K-Ras-pancreatic ductal
epithelial cells.
REFERENCES
1 Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al.
Speciﬁc killing of BRCA2-deﬁcient tumours with inhibitors of poly(ADP-ribose)
polymerase. Nature 2005; 434: 913–917.
2 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;
434: 917–921.
3 Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-
induced senescence is part of the tumorigenesis barrier imposed by DNA damage
checkpoints. Nature 2006; 444: 633–637.
4 Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al.
Oncogene-induced senescence is a DNA damage response triggered by DNA
hyper-replication. Nature 2006; 444: 638–642.
5 Gaillard H, Garcia-Muse T, Aguilera A. Replication stress and cancer. Nat Rev
Cancer 2015; 15: 276–289.
6 Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu
Rev Pathol 2015; 10: 425–448.
7 Dobbelstein M, Sorensen CS. Exploiting replicative stress to treat cancer. Nat Rev
Drug Disc 2015; 14: 405–423.
8 Carvalho JF, Kanaar R. Targeting homologous recombination-mediated DNA
repair in cancer. Expert Opin Ther Targets 2014; 18: 427–458.
9 Dietlein F, Thelen L, Reinhardt HC. Cancer-speciﬁc defects in DNA repair pathways
as targets for personalized therapeutic approaches. Trends Genet 2014; 30:
326–339.
10 Kelley MR. Future directions with DNA repair inhibitors: a roadmap for disruptive
approaches to cancer therapy In: Kelley MR (ed). DNA Repair in Cancer Therapy.
Molecular Targets and Clinical Applications 1st edn. Elsevier: Amsterdam, The
Netherlands, 2012, pp 301–310.
11 Bartek J, Mistrik M, Bartkova J. Thresholds of replication stress signaling in cancer
development and treatment. Nat Struct Mol Biol 2012; 19: 5–7.
12 Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage
response as a candidate anti-cancer barrier in early human tumorigenesis. Nature
2005; 434: 864–870.
13 Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al.
The patterns and dynamics of genomic instability in metastatic pancreatic cancer.
Nature 2010; 467: 1109–1113.
14 Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al.
Activation of the DNA damage checkpoint and genomic instability in human
precancerous lesions. Nature 2005; 434: 907–913.
15 Jackson SP, Bartek J. The DNA-damage response in human biology and disease.
Nature 2009; 461: 1071–1078.
16 Cejka P, Cannavo E, Polaczek P, Masuda-Sasa T, Pokharel S, Campbell JL et al.
DNA end resection by Dna2-Sgs1-RPA and its stimulation by Top3-Rmi1 and
Mre11-Rad50-Xrs2. Nature 2010; 467: 112–116.
17 Hoa NN, Akagawa R, Yamasaki T, Hirota K, Sasa K, Natsume T et al. Relative
contribution of four nucleases, CtIP, Dna2, Exo1 and Mre11, to the initial step of
DNA double-strand break repair by homologous recombination in both the
chicken DT40 and human TK6 cell lines. Genes Cells 2015; 20: 1059–1076.
18 Hoa NN, Kobayashi J, Omura M, Hirakawa M, Yang SH, Komatsu K et al. BRCA1 and
CtIP are both required to recruit Dna2 at double-strand breaks in homologous
recombination. PLoS ONE 2015; 10: e0124495.
19 Howard SM, Yanez DA, Stark JM. DNA damage response factors from diverse
pathways, including DNA crosslink repair, mediate alternative end joining. PLoS
Genet 2015; 11: e1004943.
20 Liao S, Toczylowski T, Yan H. Identiﬁcation of the Xenopus DNA2 protein as a
major nuclease for the 5'-43' strand-speciﬁc processing of DNA ends. Nucleic
Acids Res 2008; 36: 6091–6100.
21 Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL, Wyman C et al.
BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection
machineries for human DNA break repair. Genes Dev 2011; 25: 350–362.
22 Niu H, Chung WH, Zhu Z, Kwon Y, Zhao W, Chi P et al. Mechanism of the
ATP-dependent DNA end-resection machinery from Saccharomyces cerevisiae.
Nature 2010; 467: 108–111.
23 Zhu Z, Chung WH, Shim EY, Lee SE, Ira G. Sgs1 helicase and two nucleases dna2
and exo1 resect DNA double-strand break ends. Cell 2008; 134: 981–994.
24 Hu J, Sun L, Shen F, Chen Y, Hua Y, Liu Y et al. The intra-S phase checkpoint targets
Dna2 to prevent stalled replication forks from reversing. Cell 2012; 149:
1221–1232.
25 Thangavel S, Berti M, Levikova M, Pinto C, Gomathinayagam S, Vujanovic M et al.
DNA2 drives processing and restart of reversed replication forks in human cells.
J Cell Biol 2015; 208: 545–562.
DNA2 nuclease as a target in cancer therapy
S Kumar et al
9
Oncogenesis (2017), 1 – 10
26 Bae SH, Bae KH, Kim JA, Seo YS. RPA governs endonuclease switching during
processing of Okazaki fragments in eukaryotes. Nature 2001; 412: 456–461.
27 Budd ME, Campbell JL. A yeast replicative helicase, Dna2 helicase, interacts with
yeast FEN-1 nuclease in carrying out its essential function. Mol Cell Biol 1997; 17:
2136–2142.
28 Duxin JP, Moore HR, Sidorova J, Karanja K, Honaker Y, Dao B et al. Okazaki
fragment processing-independent role for human Dna2 enzyme during DNA
replication. J Biol Chem 2012; 287: 21980–21991.
29 Zheng L, Zhou M, Guo Z, Lu H, Qian L, Dai H et al. Human DNA2 is a mitochondrial
nuclease/helicase for efﬁcient processing of DNA replication and repair inter-
mediates. Mol Cell 2008; 32: 325–336.
30 Kumar S, Burgers PM. Lagging strand maturation factor Dna2 is a component of
the replication checkpoint initiation machinery. Genes Dev 2013; 27: 313–321.
31 Vernon M, Lobachev K, Petes TD. High rates of ‘unselected’ aneuploidy and
chromosome rearrangements in tel1 mec1 haploid yeast strains. Genetics 2008;
179: 237–247.
32 Dominguez-Valentin M, Therkildsen C, Veerla S, Jonsson M, Bernstein I, Borg A
et al. Distinct gene expression signatures in lynch syndrome and familial
colorectal cancer type x. PLoS ONE 2013; 8: e71755.
33 Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY et al. Human nuclease/helicase
DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res
2012; 72: 2802–2813.
34 Strauss C, Kornowski M, Benvenisty A, Shahar A, Masury H, Ben-Porath I et al. The
DNA2 nuclease/helicase is an estrogen-dependent gene mutated in breast and
ovarian cancers. Oncotarget 2014; 5: 9396–9409.
35 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in
pancreatic cancer and their application to treatment. Nat Rev Gastroenterol
Hepatol 2012; 9: 435–444.
36 Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605–1617.
37 Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted
developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer
2010; 10: 683–695.
38 Stewart JA, Campbell JL, Bambara RA. Dna2 is a structure-speciﬁc nuclease, with
afﬁnity for 5'-ﬂap intermediates. Nucleic Acids Res 2010; 38: 920–930.
39 Daley JM, Chiba T, Xue X, Niu H, Sung P. Multifaceted role of the Topo
IIIalpha-RMI1-RMI2 complex and DNA2 in the BLM-dependent pathway of DNA
break end resection. Nucleic Acids Res 2014; 42: 11083–11091.
40 Polo SE, Blackford AN, Chapman JR, Baskcomb L, Gravel S, Rusch A et al.
Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA
double-strand break signaling and repair. Mol Cell 2012; 45: 505–516.
41 Karanja KK, Lee EH, Hendrickson EA, Campbell JL. Preventing over-resection by
DNA2 helicase/nuclease suppresses repair defects in Fanconi anemia cells. Cell
Cycle 2014; 13: 1540–1550.
42 Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M et al. Nucleotide
deﬁciency promotes genomic instability in early stages of cancer development.
Cell 2011; 145: 435–446.
43 Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the
evolution of cancer from proliferative breast disease. Am J Pathol 1996; 148:
313–319.
44 Liu W, Zhou M, Li Z, Li H, Polaczek P, Dai H et al. A selective small molecule DNA2
inhibitor for sensitization of human cancer cells to chemotherapy. EBioMedicine
2016; 6: 73–86.
45 Lin W, Sampathi S, Dai H, Liu C, Zhou M, Hu J et al. Mammalian DNA2
helicase/nuclease cleaves G-quadruplex DNA and is required for telomere
integrity. EMBO J 2013; 32: 1425–1439.
46 Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras
promotes growth transformation and invasion of immortalized human pancreatic
cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67:
2098–2106.
47 Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M et al.
Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat
Commun 2016; 7: 10500.
48 Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR et al. BRIT1/MCPH1
links chromatin remodelling to DNA damage response. Nat Cell Biol 2009; 11:
865–872.
49 Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically
distinct pathway of mammalian chromosome break repair. PLoS Genet 2008; 4:
e1000110.
50 Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in
evaluation and validation of high throughput screening assays. J Biomol Screen
1999; 4: 67–73.
51 Holbeck SL, Collins JM, Doroshow JH. Analysis of food and drug administration-
approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol
Cancer Ther 2010; 9: 1451–1460.
Oncogenesis is an open-access journal published by Nature Publishing
Group. This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third partymaterial in this article are included
in the article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)
DNA2 nuclease as a target in cancer therapy
S Kumar et al
10
Oncogenesis (2017), 1 – 10
